1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-7-(4-piperidin-4-yl-piperazin-1-yl)-1,4-dihydro-quinoline-3-carboxylic acid | 861391-61-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-7-(4-piperidin-4-yl-piperazin-1-yl)-1,4-dihydro-quinoline-3-carboxylic acid
• 英文别名: 1-Cyclopropyl-6-fluoro-8-methoxy-4-oxo-7-(4-piperidin-4-ylpiperazin-1-yl)quinoline-3-carboxylic acid
• CAS: 861391-61-9
• 化学式: C₂₃H₂₉FN₄O₄
• 分子量: 444.506
• InChiKey: YNXSMCSZJJKRKY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  32
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  85.4
• 氢给体数：
  2
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  N-叔丁氧羰基-4-哌啶酮 、 6-哌嗪加替沙星 生成 1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-7-(4-piperidin-4-yl-piperazin-1-yl)-1,4-dihydro-quinoline-3-carboxylic acid
  参考文献：
  名称：

  [EN] RIFAMYCIN IMINO DERIVATIVES EFFECTIVE AGAINST DRUG-RESISTANT MICROBES
  [FR] DERIVES DE RIFAMYCINE IMINO EFFICACES CONTRES DES MICROBES PHARMACORESISTANTS

  摘要：

  本发明涉及具有抗微生物活性的利福霉素3-亚甲基亚胺基(-CH=N-)衍生物，包括对耐药微生物的活性。所述的利福霉素衍生物具有一个利福霉素基团，通过亚甲基亚胺基(-CH=N-)在利福霉素基团的C-3碳上与一个连接剂共价连接，而连接剂又与DNA旋转酶和拓扑异构酶IV抑制剂家族中的奎诺酮结构或其药效团共价连接。这种创新的利福霉素是新颖的，并对利福平和环丙沙星耐药微生物表现出活性。

  公开号：

  WO2005070941A1

文献信息

• Rifamycin imino derivatives effective against drug-resistant microbes
  申请人：Ding Z. Charles

  公开号：US20050209210A1

  公开（公告）日：2005-09-22

  The present invention relates to rifamycin 3-iminomethylenyl (—CH═N—) derivatives having antimicrobial activities, including activities against drug-resistant microorganisms. The claimed rifamycin derivative has a rifamycin moiety covalently linked to a linker through an iminomethylenyl (—CH═N—) group at the C-3 carbon of the rifamycin moiety and the linker is, in turn, covalently linked to a quinolone structure or its pharmacophore within the DNA gyrase and topoisomerase IV inhibitor family. The inventive rifamycins are novel and exhibit activity against both rifampin and ciprofloxacin-resistant microorganisms.

  本发明涉及具有抗微生物活性的利福霉素3-亚甲基亚胺基(—CH═N—)衍生物，包括对耐药微生物的活性。所述利福霉素衍生物具有利福霉素基团通过亚甲基亚胺基(—CH═N—)与连接基团共价连接于利福霉素基团的C-3碳，并且连接基团与DNA酶解酶和拓扑异构酶IV抑制剂家族中的喹诺酮结构或其药效团共价连接。本发明的利福霉素是新颖的，并且对利福平和环丙沙星耐药微生物均有活性。
• RIFAMYCIN IMINO DERIVATIVES EFFECTIVE AGAINST DRUG-RESISTANT MICROBES
  申请人：Cumbre Pharmaceuticals Inc.

  公开号：EP1723150A1

  公开（公告）日：2006-11-22
• US7238694B2
  申请人：——

  公开号：US7238694B2

  公开（公告）日：2007-07-03
• [EN] RIFAMYCIN IMINO DERIVATIVES EFFECTIVE AGAINST DRUG-RESISTANT MICROBES<br/>[FR] DERIVES DE RIFAMYCINE IMINO EFFICACES CONTRES DES MICROBES PHARMACORESISTANTS
  申请人：CUMBRE INC

  公开号：WO2005070941A1

  公开（公告）日：2005-08-04

  The present invention relates to rifamycin 3-iminomethylenyl (-CH=N-) derivatives having antimicrobial activities, including activities against drug-resistant microorganisms. The claimed rifamycin derivative has a rifamycin moiety covalently linked to a linker through an iminomethylenyl (-CH=N-) group at the C-3 carbon of the rifamycin moiety and the linker is, in turn, covalently linked to a quinolone structure or its pharmacophore within the DNA gyrase and topoisomerase IV inhibitor family. The inventive rifamycins are novel and exhibit activity against both rifampin and ciprofloxacin-resistant microorganisms.

  本发明涉及具有抗微生物活性的利福霉素3-亚甲基亚胺基(-CH=N-)衍生物，包括对耐药微生物的活性。所述的利福霉素衍生物具有一个利福霉素基团，通过亚甲基亚胺基(-CH=N-)在利福霉素基团的C-3碳上与一个连接剂共价连接，而连接剂又与DNA旋转酶和拓扑异构酶IV抑制剂家族中的奎诺酮结构或其药效团共价连接。这种创新的利福霉素是新颖的，并对利福平和环丙沙星耐药微生物表现出活性。